Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine and Lidocaine Combination for Trigeminal Nerve Block
NCT03865940Phase 2Completed
- Sponsor
- Vanderbilt University Medical Center
- Start
- Nov 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guanfacine in trigeminal neuralgia (TN) (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoint: Time to Return to Baseline Pain After Injection at 2 weeks. Started Nov 2019; status: completed.
02
Drugs
guanfacine
03
Conditions
trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT03865940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865940.